脑利钠肽在心血管疾病中的研究进展

Progress in Study of B-Type Natriuretic Peptide in Cardiovascular Disease

随着心力衰竭(心衰)的发展,心脏分泌物脑利钠肽(BNP)也随着增加。目前已有大量的临床研究显示BNP可作为心衰诊断和预后的生物学标志,并可用来鉴别肺源性和心源性呼吸困难,在失代偿的心衰中BNP的治疗用途更是一项新的进展。目前也有研究表明在其它的心血管病理状态,包括心肌缺血、心肌纤维化、心脏肥厚、冠状动脉内皮功能障碍和冠脉粥样硬化等BNP水平也是升高的。此外,发现轻度升高的BNP水平对将来的心血管事件有着评估预后的价值。这些发现使BNP可能成为许多心血管病理状态的最后通路。

Cardiac secretion of B-type natriuretic peptide （BNP） increases with the progression of heart failure （ HF）. A considerable number of studies has demonstrated recently that BNP could use as a biomarker for the diagnosis and prognosis of HF, to discriminate dysp- nea from cardiovascular disease or lung disease. The therapeutic use of BNP is a new advance in uncompensated HF. Several studies have shown that BNP levels increase in other cardiovascular disease states including ischemia, arrhythmias, fibrosis, cardiac hypertrophy, and coronary endothelial dysfunction. Moreover, moderate elevations of BNP have prognostic value for future cardiovascular events. These observations make it possible that BNP could represent a final pathway for many cardiovascular pathologic states.